1. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988. 37:1595–1607.
Article
2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1 : Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabetes Med. 1998. 15:539–553.
Article
3. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabetes Med. 1999. 16:442–443.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel III). JAMA. 2001. 285:2486–2497.
5. ACE position statement: Guidelines for glycemic control. Guidelines for glycemic control. Endocr Pract. 2003. 9:Suppl 1. 7–19.
8. Lim S, Lee HK, Park KS, Cho SI. Changes in the characteristics of metabolic syndrome in Korea over the period 1998~2001 as determined by Korean National Health and Nutrition Examination Surveys. Diabetes Care. 2005. 28:1810–1812.
Article
9. Ford ES. Prevalence of the metabolic syndrome defined by the international diabetes federation among adults in the US. Diabetes Care. 2005. 28:2745–2749.
Article
10. Kahn R, Ferrannini E, Buse J, Stern M. The metabolic syndrome: Time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005. 28:2289–2304.
Article
11. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003. 26:575–581.
Article
12. Meigs JB, Wilson PW, Nathan DM, D'Agostino RB Sr, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes. 2003. 52:2160–2167.
Article
13. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin-resistant. Ann Intern Med. 2003. 139:802–809.
Article
14. Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly non-diabetic men. Circulation. 1999. 100:123–128.
Article
15. Kekalainen P, Sarlund H, Pyorala K, Laakso M. Hyperinsulinemia cluster predicts the development of type 2 diabetes independent of a family history of diabetes. Diabetes Care. 1999. 22:86–92.
16. Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol. 2000. 20:538–544.
17. Kuusisto J, Lempiainen P, Mykkanen L, Laakso M. Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. Diabetes Care. 2001. 24:1629–1633.
Article
18. Onta A, Ceyhan K, Basar O, Erer B, Tobrak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels: a prospective and cross-sectional evaluation. Atherosclerosis. 2002. 165:285–292.
Article
19. Scuteri A, Najjar S, Morrell C, Lakatta E. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events. Diabetes Care. 2005. 28:882–887.
Article
20. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Dose the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004. 27:2676–2681.
Article
21. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Wiliams GR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and on all causes in United States adults. Circulation. 2004. 110:1245–1250.
Article
22. Hunt KJ, Resendez RG, Wiliams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004. 110:1251–1257.
Article